Vimarsana
Biggest News Aggregation in the World

Raphael Bueno News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Raphael Bueno. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Raphael Bueno Today - Breaking & Trending Today

BrickMark Group AG; Dynasty Global AG: Dynasty Global's D¥N to become BrickMark Group's payment token - Vimarsana News

BrickMark Group AG; Dynasty Global AG: Dynasty Global's D¥N to become BrickMark Group's payment token

Crypto Valley: Two pioneers open up the global real estate market D¥N -issuer Dynasty acquires stake in tokenization service provider BrickMarkSettlement of the investment of CHF 10 million

12 Mesothelioma Clinical Trials - How can I participate in one - Vimarsana News

12 Mesothelioma Clinical Trials - How can I participate in one

I think a common question that our viewers would have is, what do I need to do to participate in a clinical trial? Right, so, my point of view is that a very strict every trial has a very strict, very narrow window through which you can squeeze in. So I think the first thing you need to do is A: the type of mesothelioma you have. Cellular type, is that epithelial, is that mixed, is that chromatoid? Those are the number one information patient needs to know. Just saying I have mesothelioma but they really can't tell what the diagnosis is, no, shouldn't be in a trial. You gotta have the diagnos...

Researchers Identify Potential Targets for Novel Treatments for Lung Cancer - Vimarsana News

Researchers Identify Potential Targets for Novel Treatments for Lung Cancer

Date Time Researchers Identify Potential Targets for Novel Treatments for Lung Cancer Lung cancer is the most common cause of cancer deaths, accounting for about a third of all tumor-related deaths. Adenocarcinomas, a non-small cell lung cancer (NSCLC), account for about 40 percent of cancer diagnoses, but few treatments are available for the disease. A team of investigators led by Elena Levantini, PhD, a research associate in Hematology-Oncology in the laboratory of Daniel Tenen MD, at Beth Israel Deaconess Medical Center (BIDMC), evaluated a novel agent, PTC596, capable of decreasing tumor ...